Your browser doesn't support javascript.
loading
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano, Giuseppe; Gelderblom, Hans; Mach, Nicolas; Doi, Toshihiko; Tai, David; Forde, Patrick M; Sarantopoulos, John; Bedard, Philippe L; Lin, Chia-Chi; Hodi, F Stephen; Wilgenhof, Sofie; Santoro, Armando; Sabatos-Peyton, Catherine A; Longmire, Tyler A; Xyrafas, Alexandros; Sun, Haiying; Gutzwiller, Sabine; Manenti, Luigi; Naing, Aung.
Afiliación
  • Curigliano G; Istituto Europeo di Oncologia, IRCCS, and Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. giuseppe.curigliano@ieo.it.
  • Gelderblom H; Leiden University Medical Center, Leiden, the Netherlands.
  • Mach N; Oncology Department, Geneva University Hospitals, Geneva, Switzerland.
  • Doi T; National Cancer Center Hospital East, Kashiwa, Japan.
  • Tai D; National Cancer Centre Singapore, Singapore, Singapore.
  • Forde PM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Sarantopoulos J; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, Texas.
  • Bedard PL; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Lin CC; National Taiwan University Hospital, Taipei, Taiwan.
  • Hodi FS; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wilgenhof S; Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Santoro A; Humanitas University, Pieve Emanuele, and Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.
  • Sabatos-Peyton CA; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Longmire TA; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Xyrafas A; Novartis Pharma AG, Basel, Switzerland.
  • Sun H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Gutzwiller S; Novartis Pharma AG, Basel, Switzerland.
  • Manenti L; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Naing A; MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 27(13): 3620-3629, 2021 07 01.
Article en En | MEDLINE | ID: mdl-33883177
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Inhibidores de Puntos de Control Inmunológico / Anticuerpos Monoclonales / Neoplasias Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Inhibidores de Puntos de Control Inmunológico / Anticuerpos Monoclonales / Neoplasias Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Italia